Table 3.
Association between % SFRP methylation and selected demographic, lifestyle, and dietary variables in the rectum and right colon
| Counts‡ | Overall | Rectum | Right colon | |||||
|---|---|---|---|---|---|---|---|---|
| NT/NL/NR | Mean* (s.e.) | p-value§ | Mean* (s.e.) | p-value§ | Mean* (s.e.) | p-value§ | p-value ¥ | |
| Age (yrs) | ||||||||
| Q1 (30–52) | 107/107/106 | 19.3 (0.4) | 0.001 | 20.5 (0.5) | 0.001 | 18.0 (0.5) | 0.001 | 0.60 |
| Q2 (53–58) | 96/94/96 | 20.5 (0.5) | 21.3 (0.6) | 19.7 (0.6) | ||||
| Q3 (59–64) | 93/92/92 | 23.0 (0.5) | 24.5 (0.7) | 21.6 (0.6) | ||||
| Q4 (65–78) | 92/92/91 | 26.1 (0.6) | 27.4 (0.7) | 24.8 (0.8) | ||||
| Sex | ||||||||
| Male | 246/244/244 | 22.2 (0.3) | 0.75 | 23.3 (0.4) | 0.93 | 21.1 (0.4) | 0.53 | 0.52 |
| Female | 142/141/142 | 22.0 (0.4) | 23.4 (0.5) | 20.6 (0.5) | ||||
| Race | ||||||||
| White | 325/322/324 | 22.1 (0.3) | 0.0005 | 23.3 (0.3) | 0.003 | 20.9 (0.4) | 0.01 | 0.009 |
| African American | 22/22/21 | 19.7 (0.6) | 21.0 (0.9) | 18.4 (1.1) | ||||
| Hispanic | 22/22/22 | 23.7 (1.2) | 23.0 (1.5) | 24.4 (1.4) | ||||
| Other | 19/19/19 | 23.3 (1.3) | 26.6 (1.5) | 20.1 (1.5) | ||||
| Smoking | ||||||||
| Never | 164/164/163 | 21.9 (0.4) | 0.99 | 23.5 (0.5) | 0.75 | 20.2 (0.5) | 0.65 | 0.11 |
| Former | 163/162/163 | 22.4 (0.4) | 23.2 (0.5) | 21.6 (0.5) | ||||
| Current | 60/58/58 | 21.9 (0.6) | 23.2 (0.9) | 20.6 (0.8) | ||||
| Alcohol | ||||||||
| Never | 123/123/122 | 22.7 (0.5) | 0.30 | 23.9 (0.6) | 0.28 | 21.4 (0.7) | 0.54 | 0.88 |
| 1 per day | 85/83/85 | 21.8 (0.3) | 23.1 (0.4) | 20.5 (0.4) | ||||
| 2+ per day | 165/164/163 | 21.8 (0.6) | 22.9 (0.7) | 20.8 (0.6) | ||||
| Treatment | ||||||||
| placebo | 190/187/189 | 22.3 (0.4) | 0.47 | 23.8 (0.5) | 0.17 | 20.9 (0.5) | 0.88 | 0.21 |
| Folate | 198/198/196 | 21.9 (0.3) | 22.9 (0.4) | 21.0 (0.4) | ||||
| Treatment | ||||||||
| placebo | 128/126/127 | 21.6 (0.4) | 0.78 | 22.6 (0.5) | 0.30 | 20.6 (0.5) | 0.67 | 0.64 |
| Aspirin 81 | 137/137/136 | 22.6 (0.5) | 23.9 (0.5) | 21.1 (0.6) | ||||
| Aspirin 325 | 123/122/122 | 22.2 (0.5) | 23.4 (0.6) | 20.9 (0.6) | ||||
| Multivitamin use% | ||||||||
| No | 256/255/253 | 22.4 (0.4) | 0.11 | 23.7 (0.4) | 0.14 | 21.2 (0.5) | 0.31 | 0.71 |
| Yes | 130/130/130 | 21.7 (0.3) | 22.8 (0.4) | 20.6 (0.4) | ||||
| Dietary folate (mcg/day) | ||||||||
| Q1 (78.08–205.86) | 94/94/93 | 21.9 (0.5) | 0.58 | 23.3 (0.6) | 0.46 | 20.6 (0.5) | 0.77 | 0.73 |
| Q2 (205.87–277.3) | 94/93/94 | 22.3 (0.5) | 23.2 (0.6) | 21.4 (0.8) | ||||
| Q3 (277.31–373.65) | 94/93/93 | 21.7 (0.6) | 22.8 (0.7) | 20.6 (0.6) | ||||
| Q4 (376.17–1285.59) | 93/91/92 | 22.5 (0.5) | 24.0 (0.6) | 21.1 (0.7) | ||||
| Dietary protein (g/day) | ||||||||
| Q1 17.00–44.91 | 94/93/93 | 22.7 (0.5) | 0.005 | 23.6 (0.6) | 0.10 | 21.7 (0.7) | 0.004 | 0.40 |
| Q2 45.15–60.32 | 94/92/94 | 22.9 (0.5) | 23.8 (0.6) | 22.0 (0.7) | ||||
| Q3 60.70–78.71 | 94/94/93 | 22.0 (0.5) | 23.7 (0.6) | 20.4 (0.6) | ||||
| Q4 78.82–144.62 | 93/92/92 | 20.8 (0.5) | 22.1 (0.6) | 19.6 (0.6) | ||||
‡
NT = total individuals; NL = total individuals with samples on the left side; NR = total individuals with samples on the right side;
§
p-value for trend;
*
Means are adjusted for age, sex, randomized folate treatment assignment, smoking status, alcohol intake and adenoma occurrence during the 3-year randomized period.
¥
P for interaction.
%
Multivitamins used during the trial did not contain folic acid.